Nuclear Medicine and Molecular Imaging

The Korean Society of Nuclear Medicine (대한핵의학회)
권호 표지

Significant Mismatch between FDG Uptake and Size after Chemotherapy in a Patient with Non-small Cell Lung Cancer

항암치료 후에 병변의 크기는 감소하였으나 FDG 섭취는 증가한 비소세포폐암 환자 1예

  • Kwon, Seong-Young (Department of Nuclear Medicine, Chonnam National University Medical School) ;
  • Jeong, Shin-Young (Department of Nuclear Medicine, Chonnam National University Medical School) ;
  • Seo, Young-Soon (Department of Nuclear Medicine, Chonnam National University Medical School) ;
  • Ha, Jung-Min (Department of Nuclear Medicine, Chonnam National University Medical School) ;
  • Chong, A-Ri (Department of Nuclear Medicine, Chonnam National University Medical School) ;
  • Oh, Jong-Ryool (Department of Nuclear Medicine, Chonnam National University Medical School) ;
  • Song, Ho-Chun (Department of Nuclear Medicine, Chonnam National University Medical School) ;
  • Min, Jung-Joon (Department of Nuclear Medicine, Chonnam National University Medical School) ;
  • Bom, Hee-Seung (Department of Nuclear Medicine, Chonnam National University Medical School)
  • 권성영 (전남대학교 의과대학 핵의학교실) ;
  • 정신영 (전남대학교 의과대학 핵의학교실) ;
  • 서영순 (전남대학교 의과대학 핵의학교실) ;
  • 하정민 (전남대학교 의과대학 핵의학교실) ;
  • 정아리 (전남대학교 의과대학 핵의학교실) ;
  • 오종률 (전남대학교 의과대학 핵의학교실) ;
  • 송호천 (전남대학교 의과대학 핵의학교실) ;
  • 민정준 (전남대학교 의과대학 핵의학교실) ;
  • 범희승 (전남대학교 의과대학 핵의학교실)
  • Published : 2008.12.31
Download PDF
⟨ Previous Next ⟩

Abstract

A 75-year-old man with non-small cell lung cancer (NSCLC) underwent F-18 fluorodeoxyglucose (FDG) PET/CT for staging. PET/CT showed distant metastases to intra-abdominal lymph nodes (LNs) as well as bilateral mediastinal LNs (stage IV), He underwent PET/CT (restaging PET/CT) 1week after the completion of first-line chemotherapy (docetaxel+carboplatin). It showed markedly increased FDG uptake in primary tumor, whereas tumor size decreased significantly, compared to prior PET/CT. This lesion was aggravated on follow-up CT 3 months after the completion of chemotherapy. Although there are several reports that FDG PET has potential to evaluate early response to chemotherapy and prognosis, there are a few cases to show mismatch between FDG uptake and size on PET/CT. Thus we report a case of NSCLC showed increased FDG uptake of primary tumor while decreased tumor size on restaging PET/CT.

Keywords

References

  1. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-16 https://doi.org/10.1093/jnci/92.3.205
  2. Hoekstra CJ, Hoekstra OS, Stroobants SG, Vansteenkiste J, Nuyts J, Smit EF et al. Methods to monitor response to chemotherapy in non-small cell lung cancer with $^{18}F-FDG$ PET. J Nucl Med 2002;43:1304-9
  3. Cerfolio RJ, Bryant AS, Winokur TS, Ohja B, Bartolucci AA. Repeat FDG-PET after neoadjuvant therapy is a predictor of pathologic response in patients with non-small cell lung cancer. Ann Thorac Surg 2004;78:1903-9 https://doi.org/10.1016/j.athoracsur.2004.06.102
  4. Nahmias C, Hanna WT, Wahl LM, Long MJ, Hubner KF, Townsend DW. Time course of early response to chemotherapy in non-small cell lung cancer patients with $^{18}F-FDG$ PET/CT. J Nucl Med 2007;48:744-51 https://doi.org/10.2967/jnumed.106.038513
  5. De Geus-Oei LF, van der Heijden HF, Visser EP, Hermsen R, van Hoorn BA, Timmer-Bonte JN, et al. Chemotherapy response evaluation with $^{18}F-FDG$ PET in patients with non-small cell lung cancer. J Nucl Med 2007;48:1592-8 https://doi.org/10.2967/jnumed.107.043414
  6. Gottesman MM, Fojo T, Bates SE. Multidrug resistance in cancer: role of ATP dependent transporters. Nat Rev Cancer 2002;2:48-58 https://doi.org/10.1038/nrc706
  7. Kannan S. Free radical theory of autoimmunity. Theor Biol Med Model 2006;7:3-22
  8. Gu J, Yamamoto H, Fukunaga H, Danno K, Takemasa I, Ikeda M, et al. Correlation of GLUT-1 overexpression, tumor size, and depth of invasion with $^{18}F-2-fluoro-2-deoxy-D-glucose$ uptake by positron emission tomography in colorectal cancer. Dig Dis Sci 2006;51: 2198-205 https://doi.org/10.1007/s10620-006-9428-2
  9. Di Paolo A, Bocci G. Drug distribution in tumors: mechanisms, role in drug resistance, and methods for modification. Curr Oncol Rep 2007;9:109-14 https://doi.org/10.1007/s11912-007-0006-3
  10. Wyss MT, Honer M, Schubiger PA, Ametamey SM. NanoPET imaging of [$^{18}F$] fluoromisonidazole uptake in experimental mouse tumours. Eur J Nucl Med Mol Imaging 2006;33:311-8 https://doi.org/10.1007/s00259-005-1951-4
  11. Zanzonico P, Campa J, Polycarpe-Holman D, Forster G, Finn R, Larson S, et al. Animal-specific positioning molds for registration of repeat imaging studies: comparative microPET imaging of $^{18}F-labeled$ fluoro-deoxyglucose and fluoro-misonidazole in rodent tumors. Nucl Med Biol 2006;33:65-70 https://doi.org/10.1016/j.nucmedbio.2005.07.011
  12. Tanaka T, Furukawa T, Fujieda S, Kasamatsu S, Yonekura Y, Fujibayashi Y. Double-tracer autoradiography with Cu-ATSM/FDG and immunohistochemical interpretation in four different mouse implanted tumor models. Nucl Med Biol 2006;33:743-50 https://doi.org/10.1016/j.nucmedbio.2006.05.005
  13. Mankoff DA, Dunnwald LK, Gralow JR, Ellis GK, Charlop A, Lawton TJ, et al. Blood flow and metabolism in locally advanced breast cancer: relationship to response to therapy. J Nucl Med 2002;43:500-9